Antengene Corporation Limited (HK:6996) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Antengene Corporation Limited has announced that the Thailand Food and Drug Administration approved its New Drug Application for XPOVIO® to treat multiple myeloma in certain adult patients, marking another milestone for the company’s expanding oncology portfolio in the Asia Pacific region. XPOVIO® is recognized as the first orally-available selective inhibitor of the nuclear export protein XPO1, and Antengene aims to continue its mission of ‘Treating Patients Beyond Borders’ with innovative cancer treatments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.